<DOC>
	<DOC>NCT00601874</DOC>
	<brief_summary>The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine Tablets, 5 mg, to SALAGENÂ® Tablets, 5 mg (MGI Pharma) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.</brief_summary>
	<brief_title>Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Pilocarpine or any comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>